Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06267365
Other study ID # 23-00766
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 27, 2023
Est. completion date September 1, 2025

Study information

Verified date February 2024
Source NYU Langone Health
Contact Lisa Doan, MD
Phone 212-263-5072
Email Lisa.doan@nyulangone.org
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is an observational prospective study to develop predictive biomarkers for pain response in participants with chronic pancreatitis scheduled for endoscopic therapy. Participants will undergo baseline assessments including electroencephalography (EEG), quantitative sensory testing (QST), and psychosocial questionnaires. Response to endoscopic therapy will be assessed at approximately 3, 6, 12 and 18 months post-procedure using questionnaires.


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date September 1, 2025
Est. primary completion date June 1, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - adults older than 18 years; - Cambridge III or IV criteria for CP; or M-ANNHEIM criteria for definitive chronic pancreatitis; - scheduled for endoscopic therapy for ductal obstruction (may include lithotripsy, pancreatic duct dilation, or stone extraction to facilitate successful stenting) as part of routine clinical care based on multidisciplinary review; - pain present for = 3 days per week for = 3 months; - average pain over the last week = 4 on a 11-point numeric rating scale (NRS). Exclusion Criteria: - chronic pain syndrome other than CP; - episode of acute pancreatitis within 2 months of enrollment; - endoscopic therapy including ERCP, EUS Guided Celiac Plexus Block or pancreatic surgery < 6 months prior to enrollment; - active illicit drug use (excludes marijuana use); - American Society of Anesthesiologists classification > 3; - immune-mediated pancreatitis or associated pancreatic neoplasms - Major neurological disease such as stroke, uncontrolled epilepsy, dementia - Diagnosis of schizophrenia - Chronic benzodiazepine use. Use of short acting benzodiazepine on as needed basis is acceptable if participant is able to hold benzodiazepine prior to EEG recording. - Pregnancy

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States NYU Langone Health New York New York

Sponsors (2)

Lead Sponsor Collaborator
NYU Langone Health National Institute of Neurological Disorders and Stroke (NINDS)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from Baseline in Brief Pain Inventory (BPI) Score at Month 3 Post-Operation BPI is a 9-item assessment of pain. Each item is rated on a Likert scale from 0 (No Pain) to 10 (Pain as bad as you can imagine). The total score is the sum of responses and ranges from 0-90; higher scores indicate greater pain. Baseline, Month 3 Post-Operation
Secondary Change from Baseline in BPI Score at Month 6 Post-Operation BPI is a 9-item assessment of pain. Each item is rated on a Likert scale from 0 (No Pain) to 10 (Pain as bad as you can imagine). The total score is the sum of responses and ranges from 0-90; higher scores indicate greater pain. Baseline, Month 6 Post-Operation
Secondary Change from Baseline in BPI Score at Month 12 Post-Operation BPI is a 9-item assessment of pain. Each item is rated on a Likert scale from 0 (No Pain) to 10 (Pain as bad as you can imagine). The total score is the sum of responses and ranges from 0-90; higher scores indicate greater pain. Baseline, Month 12 Post-Operation
Secondary Change from Baseline in BPI Score at Month 18 Post-Operation BPI is a 9-item assessment of pain. Each item is rated on a Likert scale from 0 (No Pain) to 10 (Pain as bad as you can imagine). The total score is the sum of responses and ranges from 0-90; higher scores indicate greater pain. Baseline, Month 18 Post-Operation
Secondary Change from Baseline in Patient Reported Outcome System (PROMIS) - Physical Function - Short Form 6b Score at Month 3 Post-Operation The PROMIS Physical Function Short Form 6b comprises 6 questions assessing general physical function. Each item is rated on a Likert scale from 1 (Unable to do) to 5 (Without any difficulty). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater physical function. Baseline, Month 3 Post-Operation
Secondary Change from Baseline in PROMIS - Physical Function - Short Form 6b Score at Month 6 Post-Operation The PROMIS Physical Function Short Form 6b comprises 6 questions assessing general physical function. Each item is rated on a Likert scale from 1 (Unable to do) to 5 (Without any difficulty). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater physical function. Baseline, Month 6 Post-Operation
Secondary Change from Baseline in PROMIS - Physical Function - Short Form 6b Score at Month 12 Post-Operation The PROMIS Physical Function Short Form 6b comprises 6 questions assessing general physical function. Each item is rated on a Likert scale from 1 (Unable to do) to 5 (Without any difficulty). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater physical function. Baseline, Month 12 Post-Operation
Secondary Change from Baseline in PROMIS - Physical Function - Short Form 6b Score at Month 18 Post-Operation The PROMIS Physical Function Short Form 6b comprises 6 questions assessing general physical function. Each item is rated on a Likert scale from 1 (Unable to do) to 5 (Without any difficulty). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater physical function. Baseline, Month 18 Post-Operation
Secondary Number of Participants who use Opioids at Baseline Baseline
Secondary Number of Participants who use Opioids at Month 3 Month 3
Secondary Number of Participants who use Opioids at Month 6 Month 6
Secondary Number of Participants who use Opioids at Month 12 Month 12
Secondary Number of Participants who use Opioids at Month 18 Month 18
Secondary Change from Baseline in PROMIS - Depression - Short Form 4a Score at Month 3 Post-Procedure The PROMIS Depression - Short Form 4a is a 4-item assessment of symptoms of depression in the past 7 days. Items are ranked on a Likert scale from 1 (never) to 5 (always). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of depressive symptoms. Baseline, Month 3 Post-Procedure
Secondary Change from Baseline in PROMIS - Depression - Short Form 4a Score at Month 6 Post-Procedure The PROMIS Depression - Short Form 4a is a 4-item assessment of symptoms of depression in the past 7 days. Items are ranked on a Likert scale from 1 (never) to 5 (always). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of depressive symptoms. Baseline, Month 6 Post-Procedure
Secondary Change from Baseline in PROMIS - Depression - Short Form 4a Score at Month 12 Post-Procedure The PROMIS Depression - Short Form 4a is a 4-item assessment of symptoms of depression in the past 7 days. Items are ranked on a Likert scale from 1 (never) to 5 (always). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of depressive symptoms. Baseline, Month 12 Post-Procedure
Secondary Change from Baseline in PROMIS - Depression - Short Form 4a Score at Month 18 Post-Procedure The PROMIS Depression - Short Form 4a is a 4-item assessment of symptoms of depression in the past 7 days. Items are ranked on a Likert scale from 1 (never) to 5 (always). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of depressive symptoms. Baseline, Month 18 Post-Procedure
Secondary Change from Baseline in PROMIS - Anxiety- Short Form 4a Score at Month 3 Post-Procedure The PROMIS Anxiety- Short Form 4a is a 4-item assessment of symptoms of anxiety in the past 7 days. Items are ranked on a Likert scale from 1 (never) to 5 (always). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of anxiety. Baseline, Month 3 Post-Procedure
Secondary Change from Baseline in PROMIS - Anxiety- Short Form 4a Score at Month 6 Post-Procedure The PROMIS Anxiety- Short Form 4a is a 4-item assessment of symptoms of anxiety in the past 7 days. Items are ranked on a Likert scale from 1 (never) to 5 (always). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of anxiety. Baseline, Month 6 Post-Procedure
Secondary Change from Baseline in PROMIS - Anxiety- Short Form 4a Score at Month 12 Post-Procedure The PROMIS Anxiety- Short Form 4a is a 4-item assessment of symptoms of anxiety in the past 7 days. Items are ranked on a Likert scale from 1 (never) to 5 (always). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of anxiety. Baseline, Month 12 Post-Procedure
Secondary Change from Baseline in PROMIS - Anxiety- Short Form 4a Score at Month 18 Post-Procedure The PROMIS Anxiety- Short Form 4a is a 4-item assessment of symptoms of anxiety in the past 7 days. Items are ranked on a Likert scale from 1 (never) to 5 (always). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of anxiety. Baseline, Month 18 Post-Procedure
Secondary Change from Baseline in PROMIS - Neuropathic Pain Quality 5a Score at Month 3 Post-Procedure The PROMIS Neuropathic Pain Quality 5a is a 5-item assessment of symptoms of neuropathic pain in the past 7 days. Items are ranked on a Likert scale from 1 (not at all) to 5 (very much). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of neuropathic pain. Baseline, Month 3 Post-Procedure
Secondary Change from Baseline in PROMIS - Neuropathic Pain Quality 5a Score at Month 6 Post-Procedure The PROMIS Neuropathic Pain Quality 5a is a 5-item assessment of symptoms of neuropathic pain in the past 7 days. Items are ranked on a Likert scale from 1 (not at all) to 5 (very much). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of neuropathic pain. Baseline, Month 6 Post-Procedure
Secondary Change from Baseline in PROMIS - Neuropathic Pain Quality 5a Score at Month 12 Post-Procedure The PROMIS Neuropathic Pain Quality 5a is a 5-item assessment of symptoms of neuropathic pain in the past 7 days. Items are ranked on a Likert scale from 1 (not at all) to 5 (very much). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of neuropathic pain. Baseline, Month 12 Post-Procedure
Secondary Change from Baseline in PROMIS - Neuropathic Pain Quality 5a Score at Month 18 Post-Procedure The PROMIS Neuropathic Pain Quality 5a is a 5-item assessment of symptoms of neuropathic pain in the past 7 days. Items are ranked on a Likert scale from 1 (not at all) to 5 (very much). The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of neuropathic pain. Baseline, Month 18 Post-Procedure
Secondary Change from Baseline in PROMIS - Sleep Disturbance - Short Form 6a Score at Month 3 Post-Procedure The PROMIS Sleep Disturbance - Short Form 6a is a 6-item assessment of sleep disturbance in the past 7 days. Items are ranked on a Likert scale from 1-5. The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of sleep disturbance. Baseline, Month 3 Post-Procedure
Secondary Change from Baseline in PROMIS - Sleep Disturbance - Short Form 6a Score at Month 6 Post-Procedure The PROMIS Sleep Disturbance - Short Form 6a is a 6-item assessment of sleep disturbance in the past 7 days. Items are ranked on a Likert scale from 1-5. The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of sleep disturbance. Baseline, Month 6 Post-Procedure
Secondary Change from Baseline in PROMIS - Sleep Disturbance - Short Form 6a Score at Month 12 Post-Procedure The PROMIS Sleep Disturbance - Short Form 6a is a 6-item assessment of sleep disturbance in the past 7 days. Items are ranked on a Likert scale from 1-5. The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of sleep disturbance. Baseline, Month 12 Post-Procedure
Secondary Change from Baseline in PROMIS - Sleep Disturbance - Short Form 6a Score at Month 18 Post-Procedure The PROMIS Sleep Disturbance - Short Form 6a is a 6-item assessment of sleep disturbance in the past 7 days. Items are ranked on a Likert scale from 1-5. The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of sleep disturbance. Baseline, Month 18 Post-Procedure
Secondary Change from Baseline in PROMIS - Fatigue - Short Form 6a Score at Month 3 Post-Procedure The PROMIS Fatigue - Short Form 6a is a 6-item assessment of fatigue in the past 7 days. Items are ranked on a Likert scale from 1-5. The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of fatigue. Baseline, Month 3 Post-Procedure
Secondary Change from Baseline in PROMIS - Fatigue - Short Form 6a Score at Month 6 Post-Procedure The PROMIS Fatigue - Short Form 6a is a 6-item assessment of fatigue in the past 7 days. Items are ranked on a Likert scale from 1-5. The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of fatigue. Baseline, Month 6 Post-Procedure
Secondary Change from Baseline in PROMIS - Fatigue - Short Form 6a Score at Month 12 Post-Procedure The PROMIS Fatigue - Short Form 6a is a 6-item assessment of fatigue in the past 7 days. Items are ranked on a Likert scale from 1-5. The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of fatigue. Baseline, Month 12 Post-Procedure
Secondary Change from Baseline in PROMIS - Fatigue - Short Form 6a Score at Month 18 Post-Procedure The PROMIS Fatigue - Short Form 6a is a 6-item assessment of fatigue in the past 7 days. Items are ranked on a Likert scale from 1-5. The raw score is the sum of responses and is transformed into a T-score a mean of 50 and standard deviation of 10. Scores range from 0-100; higher scores indicate greater prevalence of fatigue. Baseline, Month 18 Post-Procedure
Secondary Change from Baseline in Pain Catastrophizing Scale (PCS) Score at Month 3 Post-Procedure The PCS is a 13-item assessment of the prevalence of thoughts and feelings associated with pain. Each item is rated on a Likert scale from 0 (not at all) to 4 (all the time). The total score is the sum of responses and ranges from 0 to 52; higher scores indicate greater pain catastrophizing. Baseline, Month 3 Post-Procedure
Secondary Change from Baseline in PCS Score at Month 6 Post-Procedure The PCS is a 13-item assessment of the prevalence of thoughts and feelings associated with pain. Each item is rated on a Likert scale from 0 (not at all) to 4 (all the time). The total score is the sum of responses and ranges from 0 to 52; higher scores indicate greater pain catastrophizing. Baseline, Month 6 Post-Procedure
Secondary Change from Baseline in PCS Score at Month 12 Post-Procedure The PCS is a 13-item assessment of the prevalence of thoughts and feelings associated with pain. Each item is rated on a Likert scale from 0 (not at all) to 4 (all the time). The total score is the sum of responses and ranges from 0 to 52; higher scores indicate greater pain catastrophizing. Baseline, Month 12 Post-Procedure
Secondary Change from Baseline in PCS Score at Month 18 Post-Procedure The PCS is a 13-item assessment of the prevalence of thoughts and feelings associated with pain. Each item is rated on a Likert scale from 0 (not at all) to 4 (all the time). The total score is the sum of responses and ranges from 0 to 52; higher scores indicate greater pain catastrophizing. Baseline, Month 18 Post-Procedure
Secondary Change from Baseline in Sleep Duration at Month 3 Post-Procedure Baseline, Month 3 Post-Procedure
Secondary Change from Baseline in Sleep Duration at Month 6 Post-Procedure Baseline, Month 6 Post-Procedure
Secondary Change from Baseline in Sleep Duration at Month 12 Post-Procedure Baseline, Month 12 Post-Procedure
Secondary Change from Baseline in Sleep Duration at Month 18 Post-Procedure Baseline, Month 18 Post-Procedure
Secondary Change from Baseline in Tobacco, Alcohol, Prescription medications, and other Substance (TAPS) Score at Month 3 Post-Procedure TAPS consists of a combined screening component (TAPS-1) followed by a brief followed by a brief assessment (TAPS-2) for those who screen positive. Scores on these questions generate a risk level per substance endorsed, based on a range of possible scores per substance. Scores range from 0-4; higher scores indicate a higher likelihood of problematic substance use. Baseline, Month 3 Post-Procedure
Secondary Change from Baseline in TAPS Score at Month 6 Post-Procedure TAPS consists of a combined screening component (TAPS-1) followed by a brief followed by a brief assessment (TAPS-2) for those who screen positive. Scores on these questions generate a risk level per substance endorsed, based on a range of possible scores per substance. Scores range from 0-4; higher scores indicate a higher likelihood of problematic substance use. Baseline, Month 6 Post-Procedure
Secondary Change from Baseline in TAPS Score at Month 12 Post-Procedure TAPS consists of a combined screening component (TAPS-1) followed by a brief followed by a brief assessment (TAPS-2) for those who screen positive. Scores on these questions generate a risk level per substance endorsed, based on a range of possible scores per substance. Scores range from 0-4; higher scores indicate a higher likelihood of problematic substance use. Baseline, Month 12 Post-Procedure
Secondary Change from Baseline in TAPS Score at Month 18 Post-Procedure TAPS consists of a combined screening component (TAPS-1) followed by a brief followed by a brief assessment (TAPS-2) for those who screen positive. Scores on these questions generate a risk level per substance endorsed, based on a range of possible scores per substance. Scores range from 0-4; higher scores indicate a higher likelihood of problematic substance use. Baseline, Month 18 Post-Procedure
Secondary Change from Baseline in Patient Global Impression of Change (PGIC) Score at Month 3 Post-Procedure PGIC is a 1-item assessment of patient's perception of the change in activity limitation, symptoms, emotions and overall quality of life related to their condition since beginning treatment. The item is rated on a scale from 1 (no change) to 7 (a great deal better). The final score is the numerical rating; higher scores indicate greater change. Baseline, Month 3 Post-Procedure
Secondary Change from Baseline in PGIC Score at Month 6 Post-Procedure PGIC is a 1-item assessment of patient's perception of the change in activity limitation, symptoms, emotions and overall quality of life related to their condition since beginning treatment. The item is rated on a scale from 1 (no change) to 7 (a great deal better). The final score is the numerical rating; higher scores indicate greater change. Baseline, Month 6 Post-Procedure
Secondary Change from Baseline in PGIC Score at Month 12 Post-Procedure PGIC is a 1-item assessment of patient's perception of the change in activity limitation, symptoms, emotions and overall quality of life related to their condition since beginning treatment. The item is rated on a scale from 1 (no change) to 7 (a great deal better). The final score is the numerical rating; higher scores indicate greater change. Baseline, Month 12 Post-Procedure
Secondary Change from Baseline in PGIC Score at Month 18 Post-Procedure PGIC is a 1-item assessment of patient's perception of the change in activity limitation, symptoms, emotions and overall quality of life related to their condition since beginning treatment. The item is rated on a scale from 1 (no change) to 7 (a great deal better). The final score is the numerical rating; higher scores indicate greater change. Baseline, Month 18 Post-Procedure
Secondary Change from Baseline in Patient Health Questionnaire-2 (PHQ-2) Score at Month 3 Post-Procedure PHQ-2 is a 2-item assessment of patient health in the last 2 weeks. Items are rated on a Likert scale from 0 (not at all) to 3 (nearly every day). The total score is the sum of responses and ranges from 0 to 6; lower scores indicate better health. Baseline, Month 3 Post-Procedure
Secondary Change from Baseline in PHQ-2 Score at Month 6 Post-Procedure PHQ-2 is a 2-item assessment of patient health in the last 2 weeks. Items are rated on a Likert scale from 0 (not at all) to 3 (nearly every day). The total score is the sum of responses and ranges from 0 to 6; lower scores indicate better health. Baseline, Month 6 Post-Procedure
Secondary Change from Baseline in PHQ-2 Score at Month 12 Post-Procedure PHQ-2 is a 2-item assessment of patient health in the last 2 weeks. Items are rated on a Likert scale from 0 (not at all) to 3 (nearly every day). The total score is the sum of responses and ranges from 0 to 6; lower scores indicate better health. Baseline, Month 12 Post-Procedure
Secondary Change from Baseline in PHQ-2 Score at Month 18 Post-Procedure PHQ-2 is a 2-item assessment of patient health in the last 2 weeks. Items are rated on a Likert scale from 0 (not at all) to 3 (nearly every day). The total score is the sum of responses and ranges from 0 to 6; lower scores indicate better health. Baseline, Month 18 Post-Procedure
Secondary Change from Baseline in Generalized Anxiety Disorder 2 (GAD-2) Score at Month 3 Post-Procedure GAD-2 is a 2-item assessment of symptoms of anxiety in the past two weeks. Items are rated on a Likert scale from 0 (not at all) to 3 (nearly every day).The total score is the sum of responses and ranges from 0-6; higher scores indicate greater symptoms of anxiety. Baseline, Month 3 Post-Procedure
Secondary Change from Baseline in GAD-2 Score at Month 6 Post-Procedure GAD-2 is a 2-item assessment of symptoms of anxiety in the past two weeks. Items are rated on a Likert scale from 0 (not at all) to 3 (nearly every day).The total score is the sum of responses and ranges from 0-6; higher scores indicate greater symptoms of anxiety. Baseline, Month 6 Post-Procedure
Secondary Change from Baseline in GAD-2 Score at Month 12 Post-Procedure GAD-2 is a 2-item assessment of symptoms of anxiety in the past two weeks. Items are rated on a Likert scale from 0 (not at all) to 3 (nearly every day).The total score is the sum of responses and ranges from 0-6; higher scores indicate greater symptoms of anxiety. Baseline, Month 12 Post-Procedure
Secondary Change from Baseline in GAD-2 Score at Month 18 Post-Procedure GAD-2 is a 2-item assessment of symptoms of anxiety in the past two weeks. Items are rated on a Likert scale from 0 (not at all) to 3 (nearly every day).The total score is the sum of responses and ranges from 0-6; higher scores indicate greater symptoms of anxiety. Baseline, Month 18 Post-Procedure
Secondary Change from Baseline in Pain, Enjoyment of Life and General Activity (PEG) Scale at Month 3 Post-Procedure PEG is a 3-item assessment of pain and how it interferes with activities of daily life. Each item is rated on a scale from 0 (does not interfere) to 10 (completely interferes). The total score is the average of the 3 items and ranges from 0-10; higher scores indicate greater pain interference. Baseline, Month 3 Post-Procedure
Secondary Change from Baseline in PEG Scale at Month 6 Post-Procedure PEG is a 3-item assessment of pain and how it interferes with activities of daily life. Each item is rated on a scale from 0 (does not interfere) to 10 (completely interferes). The total score is the average of the 3 items and ranges from 0-10; higher scores indicate greater pain interference. Baseline, Month 6 Post-Procedure
Secondary Change from Baseline in PEG Scale at Month 12 Post-Procedure PEG is a 3-item assessment of pain and how it interferes with activities of daily life. Each item is rated on a scale from 0 (does not interfere) to 10 (completely interferes). The total score is the average of the 3 items and ranges from 0-10; higher scores indicate greater pain interference. Baseline, Month 12 Post-Procedure
Secondary Change from Baseline in PEG Scale at Month 18 Post-Procedure PEG is a 3-item assessment of pain and how it interferes with activities of daily life. Each item is rated on a scale from 0 (does not interfere) to 10 (completely interferes). The total score is the average of the 3 items and ranges from 0-10; higher scores indicate greater pain interference. Baseline, Month 18 Post-Procedure
See also
  Status Clinical Trial Phase
Completed NCT03112759 - Assessing the Utility of Cognitive Behavioral Therapy for Pain Control in Patients With Chronic Pancreatitis N/A
Enrolling by invitation NCT05410795 - Establishment and Verification of Pancreatic Volume Formula Based on Imaging
Active, not recruiting NCT02965898 - The Effect of Vitamin D Substitution on the Development of Chronic Pancreatitis N/A
Completed NCT01452217 - Non-invasive MRI to Quantify the Effect of Secretin on Pancreatic Blood Flow and Perfusion in Healthy Volunteers Phase 1
Completed NCT02868047 - Establishing Standards for Normal Pancreatic EUS N/A
Completed NCT00685087 - A Prospective Study of Natural History of Pancreatitis N/A
Completed NCT04949828 - Effect of CREON on Exocrine Pancreatic Insufficiency (EPI) Symptoms
Recruiting NCT06068426 - Incorporating Endoscopic Ultrasound and Elastography Towards Improving Outcomes of Pediatric Pancreatitis Management N/A
Active, not recruiting NCT05764629 - An Observational Study on Post-chronic Pancreatitis Diabetes Mellitus
Active, not recruiting NCT05042284 - Effect of Non-enteric Coated Enzymes Substitution on Pain in Patients With Chronic Pancreatitis N/A
Completed NCT03850977 - Is There an Association Between Chronic Pancreatitis and Pulmonary Function
Recruiting NCT05692596 - The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
Recruiting NCT06015945 - Role of Home-based Transcutaneous Electrical Acustimulation for Treatment of Pain in Patients With Chronic Pancreatitis N/A
Completed NCT04619511 - Risk Factors for Post-ESWL and Post-ERCP Pancreatitis
Completed NCT03283566 - Hydroxychloroquine and Metabolic Outcomes in Patients Undergoing TPAIT Phase 2
Recruiting NCT03434392 - QST Study: Predicting Treatment Response in Chronic Pancreatitis Using Quantitative Sensory Testing N/A
Completed NCT01318369 - Efficacy Study of Δ9-THC to Treat Chronic Abdominal Pain Phase 2
Completed NCT01430234 - Enzyme Suppletion in Exocrine Pancreatic Dysfunction Phase 4
Terminated NCT01442454 - Endoscopic Ultrasound (EUS) Features of Chronic Pancreatitis N/A
Completed NCT00755573 - Pain and Chronic Pancreatitis - Clinical End Experimental Studies Phase 2/Phase 3